---
annotation-target: 1078155220929747.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-23T07:56:02.719Z","text":"奈拉滨","updated":"2022-09-23T07:56:02.719Z","document":{"title":"Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report","link":[{"href":"urn:x-pdf:4518c933c8c4f546361294db002235c2"},{"href":"vault:/hematology-theroy/papers/leukemiaWithParaplegia/1078155220929747.pdf"}],"documentFingerprint":"4518c933c8c4f546361294db002235c2"},"uri":"vault:/hematology-theroy/papers/leukemiaWithParaplegia/1078155220929747.pdf","target":[{"source":"vault:/hematology-theroy/papers/leukemiaWithParaplegia/1078155220929747.pdf","selector":[{"type":"TextPositionSelector","start":11,"end":21},{"type":"TextQuoteSelector","exact":"Nelarabine","prefix":"%125%150%200%300%400%Case Report","suffix":"-associated myelopathyin a patie"}]}]}
>```
>%%
>*%%PREFIX%%%125%150%200%300%400%Case Report%%HIGHLIGHT%% ==Nelarabine== %%POSTFIX%%-associated myelopathyin a patie*
>%%LINK%%[[#^wlgklw58a6j|show annotation]]
>%%COMMENT%%
>奈拉滨
>%%TAGS%%
>
^wlgklw58a6j


>%%
>```annotation-json
>{"created":"2022-09-23T07:57:10.903Z","updated":"2022-09-23T07:57:10.903Z","document":{"title":"Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report","link":[{"href":"urn:x-pdf:4518c933c8c4f546361294db002235c2"},{"href":"vault:/hematology-theroy/papers/leukemiaWithParaplegia/1078155220929747.pdf"}],"documentFingerprint":"4518c933c8c4f546361294db002235c2"},"uri":"vault:/hematology-theroy/papers/leukemiaWithParaplegia/1078155220929747.pdf","target":[{"source":"vault:/hematology-theroy/papers/leukemiaWithParaplegia/1078155220929747.pdf","selector":[{"type":"TextPositionSelector","start":234,"end":778},{"type":"TextQuoteSelector","exact":"Nelarabine is a purine analogue approved for the treatment of patients with T-cell lymphoblastic lym-phoma and T-cell acute lymphoblastic leukaemia (T-ALL) that have relapsed or are refractory to two previous chemo-therapy regimens. Adverse reactions to nelarabine include neurological toxicity, the pathophysiological mechanisms ofwhich are unknown, although the administration of intrathecal therapy at therapeutic doses given concomitantly withhigh-dose systemic chemotherapy that crosses the blood–brain barrier may potentiate neurotoxicity","prefix":"era-Serra1AbstractIntroduction: ","suffix":".Case report: We report a case o"}]}]}
>```
>%%
>*%%PREFIX%%era-Serra1AbstractIntroduction:%%HIGHLIGHT%% ==Nelarabine is a purine analogue approved for the treatment of patients with T-cell lymphoblastic lym-phoma and T-cell acute lymphoblastic leukaemia (T-ALL) that have relapsed or are refractory to two previous chemo-therapy regimens. Adverse reactions to nelarabine include neurological toxicity, the pathophysiological mechanisms ofwhich are unknown, although the administration of intrathecal therapy at therapeutic doses given concomitantly withhigh-dose systemic chemotherapy that crosses the blood–brain barrier may potentiate neurotoxicity== %%POSTFIX%%.Case report: We report a case o*
>%%LINK%%[[#^s9m536ltl6|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^s9m536ltl6


>%%
>```annotation-json
>{"created":"2022-09-23T07:58:09.838Z","updated":"2022-09-23T07:58:09.838Z","document":{"title":"Nelarabine-associated myelopathy in a patient with acute lymphoblastic leukaemia: Case report","link":[{"href":"urn:x-pdf:4518c933c8c4f546361294db002235c2"},{"href":"vault:/hematology-theroy/papers/leukemiaWithParaplegia/1078155220929747.pdf"}],"documentFingerprint":"4518c933c8c4f546361294db002235c2"},"uri":"vault:/hematology-theroy/papers/leukemiaWithParaplegia/1078155220929747.pdf","target":[{"source":"vault:/hematology-theroy/papers/leukemiaWithParaplegia/1078155220929747.pdf","selector":[{"type":"TextPositionSelector","start":9669,"end":10344},{"type":"TextQuoteSelector","exact":"here was no involvement of the central nervoussystem in our patient, and this has only occurred in 2of the 14 cases published.11 She also received prophylac- tic intrathecal chemotherapy like all the other patientsdescribed. Several articles have been published suggest-ing that intrathecal therapy at therapeutic doses givenconcomitantly with high doses of systemicchemotherapy that crosses the brain–blood barriermay potentiate neurotoxicity. Dat Ngo et al.12 describeda case in which neurotoxicity from nelarabine was devel-oped following its use with concomitant intrathecal ther-apy. Currently, this combination is not described in thesummary of product characteristics.","prefix":"x-icity produced by nelarabine.T","suffix":"2In our patient, neurotoxicity o"}]}]}
>```
>%%
>*%%PREFIX%%x-icity produced by nelarabine.T%%HIGHLIGHT%% ==here was no involvement of the central nervoussystem in our patient, and this has only occurred in 2of the 14 cases published.11 She also received prophylac- tic intrathecal chemotherapy like all the other patientsdescribed. Several articles have been published suggest-ing that intrathecal therapy at therapeutic doses givenconcomitantly with high doses of systemicchemotherapy that crosses the brain–blood barriermay potentiate neurotoxicity. Dat Ngo et al.12 describeda case in which neurotoxicity from nelarabine was devel-oped following its use with concomitant intrathecal ther-apy. Currently, this combination is not described in thesummary of product characteristics.== %%POSTFIX%%2In our patient, neurotoxicity o*
>%%LINK%%[[#^mn649hi3nb|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^mn649hi3nb
